Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Inflammatory Bowel Disease Clinical Trials

A listing of Inflammatory Bowel Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (61) clinical trials

The Effect of Citrus Extract on Gastrointestinal Health

This randomized, parallel, double-blind, placebo-controlled trial aims to determine the effects of daily administration of citrus extract over a period of 8 weeks on gastrointestinal health in 2 different patient groups.


Faecal Bacteriotherapy for Ulcerative Colitis

The etiopathogenesis of ulcerative colitis (UC) is not fully understood. One of the theories of UC pathogenesis represents a pathological response of mucosal immunity to intestinal microbiota. Potential therapeutic procedure how to affect this fact is the faecal microbiota transplantation (FMT). Review of the literature on FMT suggests great potential ...


Autologous Stem Cell Transplant for Crohn's Disease

Crohn's Disease Inflammatory bowel disease, encompassing Crohn's disease (CD) and ulcerative colitis (UC), represent incurable chronic inflammatory disorders of the intestinal tract. Patients with IBD experience a chronic relapsing and remitting course of their disease, with little ability to predict when these flares will occur. The primary symptoms of IBD ...


Autologous Adipose-derived Stem Cells (ASCs) for the Treatment of Perianal Fistula in Crohn Disease: A Pilot Study

Basic information: Lipogems: Lipogems system is a disposable device for liposuction, processing and adipose tissue reinjection. Procedure takes place in a single surgical time. It's a disposable device that progressively reduces adipose tissue clusters size, washing completely pro-inflammatory oil and blood debrides through a minimal manipulation "free enzyme" in a ...


Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)

The objective of this trial is to assess if Fecal Microbiota Therapy (FMT) can reduce the risk of endoscopic recurrence of CD in patients after intestinal resection. The specific outcomes of FMT to be examined are: 1) endoscopic appearance, 2) clinical symptoms, 3) safety and tolerability, and 4) microbial diversity. ...


Dose-finding Study of Colchicine in Type 2 Diabetic Patients With Coronary Artery Disease

Mortality rate in Japanese coronary artery disease (CAD) patients has been deemed the lowest among developed countries for the long time. However, cohort study of the investigators based on the registry of 8000 patients with CAD and type 2 diabetes has shown that cardiovascular mortality of such patients even under ...


Open Label Study to Assess Safety PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis

This is a proof of concept, randomized, open label, 2-arm study of OPRX-106 in subjects with active mild to moderate ulcerative colitis. Eligible subjects will be enrolled and randomized to receive 2 mg or 8 mg of OPRX-106 administered orally, once daily for 8 weeks.


Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease

The primary objective of this trial is to assess whether a 12-week treatment with Ciprofloxacin and Rifaximin is superior to placebo to obtain endoscopic remission in adherent-invasive E. coli (AIEC)-colonized patients with ileal Crohn disease (CD), with or without involvement of the caecum or the right colon.


Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative Colitis

Patients aged 18 or over with active UC defined as a Mayo score > 3 with an endoscopic score >0 will be eligible for the study. Subjects will be excluded if they are participating in another clinical trial, are unable to give informed consent, have severe comorbid medical illness, have ...


The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis

This is a Phase 2b study in patients with moderate to severe active ulcerative colitis. Patients will either receive cobitolimod dose A, B or C at two occasions or dose B or placebo at four occasions. To ensure blindness patients receiving active treatment at two occasions will receive placebo at ...